# Commvault Systems Inc: financial statements, quarterly

CVLT · Nasdaq · CIK 1169561 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/cvlt.md) · [Financials](/companies/cvlt/financials.md) · [Filings](/companies/cvlt/filings.md) · [Insiders](/companies/cvlt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cvlt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [201](/filings/0001169561-24-000133.md) | [217](/filings/0001169561-25-000007.md) | [223 d](/filings/0001169561-26-000017.md) | [225](/filings/0001169561-25-000069.md) | [233](/filings/0001169561-25-000089.md) | [263](/filings/0001169561-26-000006.md) | [275 d](/filings/0001169561-26-000017.md) | [282](/filings/0001169561-26-000024.md) | [276](/filings/0001169561-25-000089.md) | [314](/filings/0001169561-26-000006.md) | [312 d](/filings/0001169561-26-000017.md) | [314](/filings/0001169561-26-000024.md) |
| Cost of revenue | $m | [37.9](/filings/0001169561-24-000133.md) | [39.1](/filings/0001169561-25-000007.md) | [39.1 d](/filings/0001169561-26-000017.md) | [39.8](/filings/0001169561-25-000069.md) | [42.9](/filings/0001169561-25-000089.md) | [48.6](/filings/0001169561-26-000006.md) | [47.8 d](/filings/0001169561-26-000017.md) | [50.8](/filings/0001169561-26-000024.md) | [55.0](/filings/0001169561-25-000089.md) | [59.3](/filings/0001169561-26-000006.md) | [58.0 d](/filings/0001169561-26-000017.md) | [57.6](/filings/0001169561-26-000024.md) |
| Gross profit | $m | [163](/filings/0001169561-24-000133.md) | [178](/filings/0001169561-25-000007.md) | [184 d](/filings/0001169561-26-000017.md) | [185](/filings/0001169561-25-000069.md) | [190](/filings/0001169561-25-000089.md) | [214](/filings/0001169561-26-000006.md) | [227 d](/filings/0001169561-26-000017.md) | [231](/filings/0001169561-26-000024.md) | [221](/filings/0001169561-25-000089.md) | [255](/filings/0001169561-26-000006.md) | [254 d](/filings/0001169561-26-000017.md) | [257](/filings/0001169561-26-000024.md) |
| Research and development | $m | [31.3](/filings/0001169561-24-000133.md) | [34.4](/filings/0001169561-25-000007.md) | [35.2 d](/filings/0001169561-26-000017.md) | [33.1](/filings/0001169561-25-000069.md) | [33.8](/filings/0001169561-25-000089.md) | [40.0](/filings/0001169561-26-000006.md) | [39.3 d](/filings/0001169561-26-000017.md) | [40.1](/filings/0001169561-26-000024.md) | [39.9](/filings/0001169561-25-000089.md) | [42.2](/filings/0001169561-26-000006.md) | [40.1 d](/filings/0001169561-26-000017.md) | [39.5](/filings/0001169561-26-000024.md) |
| Operating income | $m | [17.6](/filings/0001169561-24-000133.md) | [21.1](/filings/0001169561-25-000007.md) | [18.2 d](/filings/0001169561-26-000017.md) | [18.4](/filings/0001169561-25-000069.md) | [15.0](/filings/0001169561-25-000089.md) | [13.6](/filings/0001169561-26-000006.md) | [26.7 d](/filings/0001169561-26-000017.md) | [25.1](/filings/0001169561-26-000024.md) | [12.5](/filings/0001169561-25-000089.md) | [19.8](/filings/0001169561-26-000006.md) | [16.6 d](/filings/0001169561-26-000017.md) | [25.7](/filings/0001169561-26-000024.md) |
| Interest expense | $m | [0.1](/filings/0001169561-23-000145.md) | [0.1](/filings/0001169561-24-000007.md) | [0.1 d](/filings/0001169561-24-000039.md) | [0.1](/filings/0001169561-25-000069.md) | [0.1](/filings/0001169561-25-000089.md) | [0.1](/filings/0001169561-26-000006.md) | [0.1 d](/filings/0001169561-26-000017.md) | [0.3](/filings/0001169561-26-000024.md) | [0.6](/filings/0001169561-25-000089.md) | [1.4](/filings/0001169561-26-000006.md) | [1.4 d](/filings/0001169561-26-000017.md) | [1.5](/filings/0001169561-26-000024.md) |
| Income tax | $m | [5.7](/filings/0001169561-24-000133.md) | [5.2](/filings/0001169561-25-000007.md) | [(103) d](/filings/0001169561-26-000017.md) | [2.1](/filings/0001169561-25-000069.md) | [1.1](/filings/0001169561-25-000089.md) | [4.1](/filings/0001169561-26-000006.md) | [(2.4) d](/filings/0001169561-26-000017.md) | [3.4](/filings/0001169561-26-000024.md) | [0.4](/filings/0001169561-25-000089.md) | [9.2](/filings/0001169561-26-000006.md) | [8.5 d](/filings/0001169561-26-000017.md) | [11.1](/filings/0001169561-26-000024.md) |
| Net income | $m | [13.0](/filings/0001169561-24-000133.md) | [17.1](/filings/0001169561-25-000007.md) | [126 d](/filings/0001169561-26-000017.md) | [18.5](/filings/0001169561-25-000069.md) | [15.6](/filings/0001169561-25-000089.md) | [11.0](/filings/0001169561-26-000006.md) | [31.0 d](/filings/0001169561-26-000017.md) | [23.5](/filings/0001169561-26-000024.md) | [14.7](/filings/0001169561-25-000089.md) | [17.8](/filings/0001169561-26-000006.md) | [14.6 d](/filings/0001169561-26-000017.md) | [21.1](/filings/0001169561-26-000024.md) |
| Diluted EPS | $ per share | [0.29](/filings/0001169561-24-000133.md) | [0.38](/filings/0001169561-25-000007.md) | not reported | [0.41](/filings/0001169561-25-000069.md) | [0.35](/filings/0001169561-25-000089.md) | [0.24](/filings/0001169561-26-000006.md) | not reported | [0.52](/filings/0001169561-26-000024.md) | [0.33](/filings/0001169561-25-000089.md) | [0.40](/filings/0001169561-26-000006.md) | not reported | [0.50](/filings/0001169561-26-000024.md) |
| Basic EPS | $ per share | [0.30](/filings/0001169561-24-000133.md) | [0.39](/filings/0001169561-25-000007.md) | not reported | [0.42](/filings/0001169561-25-000069.md) | [0.36](/filings/0001169561-25-000089.md) | [0.25](/filings/0001169561-26-000006.md) | not reported | [0.53](/filings/0001169561-26-000024.md) | [0.33](/filings/0001169561-25-000089.md) | [0.40](/filings/0001169561-26-000006.md) | not reported | [0.51](/filings/0001169561-26-000024.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [283](/filings/0001169561-23-000145.md) | [284](/filings/0001169561-24-000007.md) | [313](/filings/0001169561-25-000034.md) | [288](/filings/0001169561-24-000080.md) | [303](/filings/0001169561-24-000133.md) | [244](/filings/0001169561-25-000007.md) | [302](/filings/0001169561-26-000017.md) | [363](/filings/0001169561-25-000069.md) | [1,064](/filings/0001169561-25-000089.md) | [1,026](/filings/0001169561-26-000006.md) | [900](/filings/0001169561-26-000024.md) | [930](/filings/0001169561-26-000024.md) |
| Current assets | $m | [540](/filings/0001169561-23-000145.md) | [567](/filings/0001169561-24-000007.md) | [595](/filings/0001169561-25-000034.md) | [551](/filings/0001169561-24-000080.md) | [563](/filings/0001169561-24-000133.md) | [577](/filings/0001169561-25-000007.md) | [635](/filings/0001169561-26-000017.md) | [667](/filings/0001169561-25-000069.md) | [1,353](/filings/0001169561-25-000089.md) | [1,445](/filings/0001169561-26-000006.md) | [1,287](/filings/0001169561-26-000024.md) | [1,267](/filings/0001169561-26-000024.md) |
| Total assets | $m | [773](/filings/0001169561-23-000145.md) | [804](/filings/0001169561-24-000007.md) | [944](/filings/0001169561-25-000034.md) | [935](/filings/0001169561-24-000080.md) | [958](/filings/0001169561-24-000133.md) | [1,024](/filings/0001169561-25-000007.md) | [1,118](/filings/0001169561-26-000017.md) | [1,176](/filings/0001169561-25-000069.md) | [1,917](/filings/0001169561-25-000089.md) | [2,038](/filings/0001169561-26-000006.md) | [1,886](/filings/0001169561-26-000024.md) | [1,890](/filings/0001169561-26-000024.md) |
| Current liabilities | $m | [404](/filings/0001169561-23-000145.md) | [433](/filings/0001169561-24-000007.md) | [485](/filings/0001169561-25-000034.md) | [447](/filings/0001169561-24-000080.md) | [468](/filings/0001169561-24-000133.md) | [512](/filings/0001169561-25-000007.md) | [555](/filings/0001169561-26-000017.md) | [536](/filings/0001169561-25-000069.md) | [535](/filings/0001169561-25-000089.md) | [617](/filings/0001169561-26-000006.md) | [658](/filings/0001169561-26-000024.md) | [620](/filings/0001169561-26-000024.md) |
| Shareholders' equity | $m | [182](/filings/0001169561-25-000007.md) | [175](/filings/0001169561-25-000007.md) | [278](/filings/0001169561-26-000017.md) | [282](/filings/0001169561-25-000089.md) | [278](/filings/0001169561-26-000006.md) | [288](/filings/0001169561-26-000006.md) | [325](/filings/0001169561-26-000024.md) | [365](/filings/0001169561-26-000024.md) | [210](/filings/0001169561-26-000006.md) | [217](/filings/0001169561-26-000006.md) | [7.5](/filings/0001169561-26-000024.md) | [52.1](/filings/0001169561-26-000024.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [40.3 d](/filings/0001169561-24-000133.md) | [44.4 d](/filings/0001169561-25-000007.md) | [80.0 d](/filings/0001169561-26-000017.md) | [44.7](/filings/0001169561-25-000069.md) | [55.6 d](/filings/0001169561-25-000089.md) | [30.1 d](/filings/0001169561-26-000006.md) | [77.0 d](/filings/0001169561-26-000017.md) | [31.7](/filings/0001169561-26-000024.md) | [76.8 d](/filings/0001169561-25-000089.md) | [4.0 d](/filings/0001169561-26-000006.md) | [132 d](/filings/0001169561-26-000017.md) | [51.7](/filings/0001169561-26-000024.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001169561-24-000133.md) | [1.8 d](/filings/0001169561-25-000007.md) | [0.9 d](/filings/0001169561-26-000017.md) | [0.9](/filings/0001169561-25-000069.md) | [1.8 d](/filings/0001169561-25-000089.md) | [0.3 d](/filings/0001169561-26-000006.md) | [0.8 d](/filings/0001169561-26-000017.md) | [1.9](/filings/0001169561-26-000024.md) | [3.2 d](/filings/0001169561-25-000089.md) | [2.1 d](/filings/0001169561-26-000006.md) | [0.3 d](/filings/0001169561-26-000017.md) | [0.6](/filings/0001169561-26-000024.md) |
| Share repurchases | $m | [31.3 d](/filings/0001169561-24-000133.md) | [51.3 d](/filings/0001169561-25-000007.md) | [50.4 d](/filings/0001169561-26-000017.md) | [51.4](/filings/0001169561-25-000069.md) | [51.9 d](/filings/0001169561-25-000089.md) | [31.9 d](/filings/0001169561-26-000006.md) | [29.8 d](/filings/0001169561-26-000017.md) | [15.1](/filings/0001169561-26-000024.md) | [131 d](/filings/0001169561-25-000089.md) | [40.7 d](/filings/0001169561-26-000006.md) | [259 d](/filings/0001169561-26-000017.md) | [10.1](/filings/0001169561-26-000024.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.5](/filings/0001169561-23-000145.md) | [44.7](/filings/0001169561-24-000007.md) | [45.0](/filings/0001169561-24-000080.md) | [44.9](/filings/0001169561-24-000133.md) | [44.8](/filings/0001169561-25-000007.md) | [45.0](/filings/0001169561-25-000069.md) | [45.1](/filings/0001169561-25-000089.md) | [45.2](/filings/0001169561-26-000006.md) | [45.3](/filings/0001169561-26-000024.md) | [45.2](/filings/0001169561-25-000089.md) | [44.6](/filings/0001169561-26-000006.md) | [41.9](/filings/0001169561-26-000024.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,444,564 at 2026-07-27, from the cover of the [10-Q filed 2026-07-29](/filings/0001169561-26-000024.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.